RIPK1 and malignant colon neoplasm: PRMT1 methylates RIP3 to inhibit RIP1-RIP3 complex formation, resulting in the impaired RIP3 phosphorylation and necroptosis activation that builds the beneficial immune microenvironment against colon cancer growth (Fig. 5J).